Recruiting

CapsoCam® Colon

Sponsor:

Capso Vision, Inc.

Code:

NCT07089615

Conditions

Colonic Polyps

Eligibility Criteria

Sex: All

Age: 45 - 70+

Healthy Volunteers: Not accepted

Interventions

Capsule swallow

Study Details

Brief summary:

Note: This is the same study protocol as NCT04607746 with slight changes to how the videos will be read and a 2nd generation capsule is being studied.

The purpose of this study is to evaluate the safety and effectiveness of CapsoCam® Colon (CV-3) endoscope system for the detection of colonic polyps and to show that AI-based CADe improves the polyp-detection accuracy and efficiency of capsule video readers. It will use colonoscopy results as a reference.

The participant will:

1. prep for and swallow a study capsule and then
2. prep for and undergo a colonoscopy either the following day or 3-6 weeks later

Conditions

Colonic Polyps

Study ID

NCT07089615

Start date

Jun 26, 2025

Status verified date

May, 2026

Completion date

Dec, 2026

Anticipated

Primary completion date

Dec, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 45 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. 45-75 years of age
2. Committed to undergo a colonoscopy.
3. Choose to participate and must have signed the IRB-approved informed consent document and agreed to release colonoscopy images and results report to Sponsor

Exclusion Criteria:

1. Colonoscopy or CT-colonography within the past 5 years that demonstrated no polyps
2. Has contraindication for capsule endoscopy or colonoscopy
3. Subject is suspected or diagnosed with familial adenomatous polyposis, hereditary non polyposis colon cancer, or any high-risk genetic syndrome
4. Subject is suspected or diagnosed with inflammatory bowel disease such as ulcerative colitis or Crohn's disease
5. History of incomplete colonoscopy
6. Type I or uncontrolled II Diabetes (Uncontrolled defined as HbA1C>6.4 within the past 3 months and/or with history of constipation or gastroparesis).
7. Impaired cardiac function assessed as greater than NYHA Class II
8. History of small- or large-bowel obstructive condition
9. Known history of swallowing disorder, and/or ischemic bowel disease neuropathies and/or radiation enteritis
10. Known history of NSAID enteropathy and stricture resulting from taking NSAIDs on a regular basis that, in the opinion of the Investigator, would put the subject at greater risk for capsule endoscope retention
11. Known allergy to ingredients used in bowel preparation and boosters
12. Daily and/or regular narcotic use
13. Decompensated cirrhosis
14. Prior abdominal radiation therapy
15. Diagnosis of anorexia or bulimia
16. History of or suspicion of any of the following: strictures, volvulus or intestinal obstruction, or internal hernias or abdominal surgeries that the Investigator believes should exclude the patient from study participation
17. Known or suspected megacolon
18. Scheduled to undergo MRI examination within 7 days after ingestion of the capsule
19. Has known slow gastric-emptying time or confirmed diagnosis of gastroparesis
20. Pregnant or nursing or of child-bearing potential and does not agree to practice medically acceptable methods of contraception. Women of child bearing potential (WOCBP) must have a negative urine pregnancy test at screening.
21. Unable to follow or tolerate fasting, bowel preparation, and other study procedures
22. Any documented medical or psychological condition or significant concurrent illness which, in the Investigator's opinion, would make it unsafe for the subject to participate in this research study or would affect the validity of the study results
23. Are currently enrolled in an interventional clinical study or currently enrolled in or within the last 30 days, a pharmaceutical clinical study
24. Chronic constipation as defined by <3 bowel movements per week, or the use of routine laxatives (other than fiber) to attain regular bowel movements

Study Design

Enrollment

330 participants

Anticipated

Intervention Model

Single group

Primary purpose

Screening

Interventions and Outcome Measures

Arms

experimental: A new capsule design is being used from that of the first phase of the study.

Interventions

Capsule swallow

Participant will swallow the investigational device

Primary outcome measure

  • Positive Percentage Agreement [ Time Frame: From capsule swallow to Colonoscopy - up to 6 weeks ]
  • Negative Percentage Agreement [ Time Frame: From Capsule swallow to colonoscopy - Up to 6 weeks ]

Central Contacts and Locations

Central contacts

Taylor Williamsen Principle CRA/Study Lead

815-861-9575taylor.williamsen@capsovision.com

Rebecca Petersen Sr. Director of Clinical Affairs

510-566-8824rebecca.petersen@capsovision.com

Locations

SB Gastro Clinical Research

Recruiting

Chula Vista, California, United States, 91910

Contacts

Principal Investigator:

Erick Alayo, M.D.

Gastro Care Institute

Recruiting

Lancaster, California, United States, 93534

Contacts

Lead Study Coordinator

661-529-7550Rvargas@gciav.com

Principal Investigator:

Kumaravel Perumalsamy, M.D.

Knowledge Research Center

Recruiting

Orange, California, United States, 92868

Contacts

Principal Investigator:

Alla Abousaif, M.D.

Advanced Research Institute

Recruiting

St. Petersburg, Florida, United States, 33710

Contacts

Principal Investigator:

Jatin Bidani, M.D.

Digestive Health Services

Recruiting

Downers Grove, Illinois, United States, 60515

Contacts

Principal Investigator:

Rockford Yapp, M.D.

Gastroenterology and Internal Medicine Specialists

Recruiting

Lake Barrington, Illinois, United States, 60010

Contacts

Principal Investigator:

Nicole Gentile, M.D.

Northshore Center for Gastroenterology

Recruiting

Libertyville, Illinois, United States, 60048

Contacts

Principal Investigator:

Sean Lee, M.D.

Suburban Gastroenterology

Recruiting

Naperville, Illinois, United States, 60540

Contacts

Principal Investigator:

Thomas Couri, M.D.

Southwest Gastroenterology

Recruiting

Oak Lawn, Illinois, United States, 60453

Contacts

Principal Investigator:

Kamran Ayub, M.D.

Gastroenterology Group of Rochester

Recruiting

Rochester, New York, United States, 14618

Contacts

Lead Study Coordinator

585-278-1116bvasciannie@ggr1.com

Principal Investigator:

Jonathan Wilmot, M.D.

Great Lakes Gastroenterology Research

Recruiting

Mentor, Ohio, United States, 44060

Contacts

Lead Clinical Research Coordinator

216-387-4966susand@greatlakesgastro.net

Principal Investigator:

Keith Friedenberg, M.D.

More Information

Sponsor

Capso Vision, Inc.

Last update posted

May 8, 2026

Last verified

May, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Capso Vision, Inc. on 2026-05-08.